Capvizr
THE DEAL, AT A GLANCE

Cloverleaf Bio

From the announcement
01
MoleculesDrug research
Medicine development
What it does] About Cloverleaf Bio Cloverleaf Bio is an RNA therapeutics company developing engineered tRNA-based therapeutics for cancer.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
02Who is involvedBacked by 4BIO Capital, strategic investors AbbVie Ventures, Eli Lilly [From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
03What happenedCloverleaf Bio raised $33M Seed, announced 2026-09-08From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
04Why it mattersCloverleaf Bio raised a $33M Seed round led by 4BIO Capital to advance engineered tRNA-based therapeutics for cancer.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Cloverleaf Bio · Financing Record

Explore source-linked visual explanations for Cloverleaf Bio. Unsupported claims are withheld while source review continues.

Record 11874 · Recorded date: 2026-09-08

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime